Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Hims & Hers has been expanding its presence in the weight management market, with its existing Novo partnership representing ...

Novo Nordisk has launched a late-stage trial for its obesity drug candidate, CagriSema, aiming to restore market confidence ...